A statement from Diabetes Australia about the withdrawal of Fiasp from the PBS 1 March 2023 Diabetes Australia has been advised that Fiasp insulin will be removed from the Pharmaceutical Benefits Scheme from 1 April 2023. This means people will no longer be able to access it at a subsidised price. Fiasp will be available for people who choose to access it via private prescription; however, this will be more expensive. We understand this is causing distress for some people living with diabetes who currently use this medication. We have conveyed our concerns to Novo Nordisk and the Government, and are continuing these discussions to see what can be done to reduce the impact on people living with diabetes who are using this medication. In the meantime, if you are using Fiasp, we strongly encourage you to make an appointment with your doctor as soon as possible to discuss alternative insulins. If you have any questions or concerns, please contact Diabetes Australia on 1800 177 055.
Blog 1 April 2026 Five less common reasons your glucose levels may be running high High glucose readings can feel frustrating, especially when you can’t see an obvious reason why. The reality is that many everyday factors such as stress, sleep, hormones and even hydration can all play a role. Continue Reading
Blog 1 April 2026 Should you be eating that? Tips on navigating food comments, stigma, and special occasions Food comments can sting, especially when you hear them at parties, family gatherings, or meals out. Here we explore the impact of food policing and diabetes stigma, and offer practical, compassionate ways to respond, set boundaries, and enjoy special occasions without guilt or explanation. Continue Reading
Media releases 31 March 2026 Health Minister and national leaders gather in Canberra as diabetes epidemic accelerates Australia’s Minister for Health and Ageing Mark Butler and the nation’s leading diabetes experts will gather at Parliament House in... Continue Reading
